137 related articles for article (PubMed ID: 10930490)
1. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.
Ramstad T; Lawnicki L; Vetto J; Weinberg A
Am J Surg; 2000 May; 179(5):400-6. PubMed ID: 10930490
[TBL] [Abstract][Full Text] [Related]
2. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
3. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.
Vetto JT; Lum S; Morris A; Sicotte M; Davis J; Lemon M; Weinberg A
Am J Surg; 1997 Sep; 174(3):258-65. PubMed ID: 9324133
[TBL] [Abstract][Full Text] [Related]
4. Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
Weinberg AD; Rivera MM; Prell R; Morris A; Ramstad T; Vetto JT; Urba WJ; Alvord G; Bunce C; Shields J
J Immunol; 2000 Feb; 164(4):2160-9. PubMed ID: 10657670
[TBL] [Abstract][Full Text] [Related]
5. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.
Morris A; Vetto JT; Ramstad T; Funatake CJ; Choolun E; Entwisle C; Weinberg AD
Breast Cancer Res Treat; 2001 May; 67(1):71-80. PubMed ID: 11518468
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
7. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).
Petty JK; He K; Corless CL; Vetto JT; Weinberg AD
Am J Surg; 2002 May; 183(5):512-8. PubMed ID: 12034383
[TBL] [Abstract][Full Text] [Related]
8. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
Weinberg AD; Wegmann KW; Funatake C; Whitham RH
J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
[TBL] [Abstract][Full Text] [Related]
9. OX-40: life beyond the effector T cell stage.
Weinberg AD; Vella AT; Croft M
Semin Immunol; 1998 Dec; 10(6):471-80. PubMed ID: 9826580
[TBL] [Abstract][Full Text] [Related]
10. [Tumor infiltrating regulatory T cells in human breast cancer and associated draining lymph nodes: an in-situ analysis].
Wang HY; Shi QF; Sun Y; He JJ; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):95-100. PubMed ID: 23710915
[TBL] [Abstract][Full Text] [Related]
11. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
12. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
[TBL] [Abstract][Full Text] [Related]
13. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
14. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ
Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492
[TBL] [Abstract][Full Text] [Related]
15. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
16. The role of axillary dissection in mammographically detected carcinoma.
Pandelidis SM; Peters KL; Walusimbi MS; Casady RL; Laux SV; Cavanaugh SH; Bauer TL
J Am Coll Surg; 1997 Apr; 184(4):341-5. PubMed ID: 9100677
[TBL] [Abstract][Full Text] [Related]
17. Association of chemotactic factor receptor 5 gene with breast cancer.
Zhang Y; Meng FY; Li WL; Zhou CX; Guan Z; Fan HY
Genet Mol Res; 2013 Nov; 12(4):5289-300. PubMed ID: 24301790
[TBL] [Abstract][Full Text] [Related]
18. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.
Faghih Z; Erfani N; Haghshenas MR; Safaei A; Talei AR; Ghaderi A
Immunol Lett; 2014; 158(1-2):57-65. PubMed ID: 24326038
[TBL] [Abstract][Full Text] [Related]
19. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction.
Noguchi S; Aihara T; Nakamori S; Motomura K; Inaji H; Imaoka S; Koyama H
Cancer; 1994 Sep; 74(5):1595-600. PubMed ID: 7520351
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
